These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 31101580)

  • 1. Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma and End-stage Renal Disease at 2 Centers.
    Tachibana H; Kondo T; Ishihara H; Takagi T; Tanabe K
    Clin Genitourin Cancer; 2019 Aug; 17(4):e772-e778. PubMed ID: 31101580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program.
    Verzoni E; Cartenì G; Cortesi E; Giannarelli D; De Giglio A; Sabbatini R; Buti S; Rossetti S; Cognetti F; Rastelli F; Sobrero A; Turci D; Sternberg CN; Porta C; Cappuzzo F; Tortora G; Tassinari D; Panni S; Pazzola A; Surico G; Raimondi A; De Giorgi U; Procopio G;
    J Immunother Cancer; 2019 Apr; 7(1):99. PubMed ID: 30944023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes and Safety of Biweekly and Monthly Nivolumab in Patients with Metastatic Renal Cell Carcinoma and Dialysis: Three Case Reports and Literature Review.
    Osmán-García I; Congregado-Ruiz CB; Lendínez-Cano G; Baena-Villamarin C; Conde-Sanchez JM; Medina-López RA
    Urol Int; 2020; 104(3-4):323-326. PubMed ID: 31914452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab.
    Ishihara H; Takagi T; Kondo T; Homma C; Tachibana H; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Urol Oncol; 2019 Jun; 37(6):355.e21-355.e29. PubMed ID: 30935847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinoma.
    Nemoto Y; Ishihara H; Nakamura K; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Tanabe K; Kondo T; Takagi T
    Int Urol Nephrol; 2022 Jan; 54(1):47-54. PubMed ID: 34704214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety profile of nivolumab for Japanese patients with metastatic renal cell cancer.
    Fujiwara R; Inamura K; Yuasa T; Numao N; Yamamoto S; Masuda H; Kawauchi A; Takeuchi K; Yonese J
    Int J Clin Oncol; 2020 Jan; 25(1):151-157. PubMed ID: 31522314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study.
    Vitale MG; Pipitone S; Venturelli M; Baldessari C; Porta C; Iannuzzi F; Basso U; Scagliarini S; Zucali PA; Galli L; Rossetti S; Caserta C; Bracarda S; Iacovelli R; Masini C; Cortellini A; Di Girolamo S; Buti S; Fornarini G; Carrozza F; Santoni M; Caputo F; Giaquinta S; Balduzzi S; D'Amico R; Vitale G; Mighali P; Sabbatini R
    Clin Genitourin Cancer; 2020 Dec; 18(6):477-488. PubMed ID: 32732112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Int J Clin Oncol; 2020 Apr; 25(4):705-712. PubMed ID: 31858306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter retrospective study of nivolumab monotherapy in previously treated metastatic renal cell carcinoma patients: interim analysis of Japanese real-world data.
    Hinata N; Yonese J; Masui S; Nakai Y; Shirotake S; Tatsugami K; Inamoto T; Nozawa M; Ueda K; Etsunaga T; Osawa T; Uemura M; Kimura G; Numakura K; Yamana K; Miyake H; Fukasawa S; Ochi K; Kaneko H; Uemura H
    Int J Clin Oncol; 2020 Aug; 25(8):1533-1542. PubMed ID: 32519026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme.
    De Giorgi U; Cartenì G; Giannarelli D; Basso U; Galli L; Cortesi E; Caserta C; Pignata S; Sabbatini R; Bearz A; Buti S; Lo Re G; Berruti A; Bracarda S; Cognetti F; Rastelli F; Fornarini G; Porta C; Turci D; Sternberg CN; Procopio G;
    BJU Int; 2019 Jan; 123(1):98-105. PubMed ID: 29956884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between Immune-related Adverse Events and Clinical Outcome Following Nivolumab Treatment in Patients With Metastatic Renal Cell Carcinoma.
    Kobayashi K; Iikura Y; Hiraide M; Yokokawa T; Aoyama T; Shikibu S; Hashimoto K; Suzuki K; Sato H; Sugiyama E; Tajima M; Hama T
    In Vivo; 2020; 34(5):2647-2652. PubMed ID: 32871795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium.
    Dudani S; Graham J; Wells JC; Bakouny Z; Pal SK; Dizman N; Donskov F; Porta C; de Velasco G; Hansen A; Iafolla M; Beuselinck B; Vaishampayan UN; Wood LA; Liow E; Yan F; Yuasa T; Bjarnason GA; Choueiri TK; Heng DYC
    Eur Urol; 2019 Dec; 76(6):861-867. PubMed ID: 31445844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between immune-related adverse events and the long-term outcomes in recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab.
    Matsuo M; Yasumatsu R; Masuda M; Toh S; Wakasaki T; Hashimoto K; Taura M; Uchi R; Nakagawa T
    Oral Oncol; 2020 Feb; 101():104525. PubMed ID: 31863963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
    Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
    BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy.
    Vitale MG; Scagliarini S; Galli L; Pignata S; Lo Re G; Berruti A; Defferrari C; Spada M; Masini C; Santini D; Ciuffreda L; Ruggeri EM; Bengala C; Livi L; Fagnani D; Bonetti A; Giustini L; Hamzaj A; Procopio G; Caserta C; Sabbatini R
    PLoS One; 2018; 13(7):e0199642. PubMed ID: 29979712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of nivolumab for renal cell carcinoma in patients over 75 years old from multiple Japanese institutes.
    Numakura K; Kobayashi M; Hatakeyama S; Naito S; Horikawa Y; Tanaka T; Kamada S; Muto Y; Yamamoto R; Koizumi A; Nara T; Kanda S; Saito M; Narita S; Inoue T; Shimoda N; Tsuchiya N; Ohyama C; Habuchi T
    Int J Clin Oncol; 2020 Aug; 25(8):1543-1550. PubMed ID: 32394047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of nivolumab as a second line therapy in metastatic renal cell carcinoma: a retrospective chart review.
    Gamulin M; Nham E; Rkman D; Antunac Golubić Z; Likić R
    Croat Med J; 2020 Aug; 61(4):326-332. PubMed ID: 32881430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
    Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.
    Koshkin VS; Barata PC; Zhang T; George DJ; Atkins MB; Kelly WJ; Vogelzang NJ; Pal SK; Hsu J; Appleman LJ; Ornstein MC; Gilligan T; Grivas P; Garcia JA; Rini BI
    J Immunother Cancer; 2018 Jan; 6(1):9. PubMed ID: 29378660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durable response after interruption of nivolumab in patients with metastatic renal cell carcinoma: Is renal toxicity a marker to predict the benefit of nivolumab?
    Kus T; Aktas G
    J Oncol Pharm Pract; 2020 Jun; 26(4):1000-1004. PubMed ID: 31594517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.